24-24 April 2023
Qmed+
REGISTER NOW
keyboard_arrow_left See all news

Recent News

30 Jan, 2023 /
Cirtec Medical
Cirtec Medical Acquires QMD™ Precision Components Business
Cirtec Medical Corporation acquires QMD’s Precision Components business
27 Jan, 2023 /
AMADA WELD TECH
AMADA WELD TECH to Highlight Innovative Solutions for Medical Device Manufacturing at MD&M West 2023
Reliability, quality, and innovation on display in booth #2935
10 Jan, 2023 /
Qosina
Qosina introduces Irradiate to Order service for single-use bioprocess components
Qosina introduces an Irradiate to Order service for its single-use bioprocess component ...
09 Jan, 2023 /
Qosina
Qosina Announces Partnership with ILC Dover and Expanded Portfolio of Liquid Bag Chambers
Qosina announces a partnership with ILC Dover, a leader in the innovative design and pro...
05 Jan, 2023 /
Life Science Outsourcing, Inc.
Life Science Outsourcing Completes Acquisition of J-Pac Medical
Expands into biomaterials and diagnostics end-markets, broadens service offerings, and s...
Phillips-Medisize, a Molex company
/ 09 Apr, 2019
keyboard_arrow_left See all news

Phillips-Medisize Connected Health Platform Now Available for Customized Connected Health Solutions

HUDSON, WI – October 30, 2018 – Phillips-Medisize, a Molex company, has completed the rollout of its innovative third-generation Connected Health Platform (CHP). The cloud-based platform provides a safe, scalable and trusted medical device data system (MDDS) for pharmaceutical companies and drug delivery device developers, offering a unique opportunity to reduce risk, cost and time to market for connected health solutions.

Incorporating more than a decade of experience in developing connected health solutions, the Phillips-Medisize CHP encompasses extensive information-sharing, analytics capabilities, robust cybersecurity and streamlined regulatory documentation.

The Phillips-Medisize CHP is built on technology from the world leader in health data interoperability and includes an advanced analytics package designed for connected drug delivery devices, biosensors and regulated Mobile Medical Applications (SaMD/MMA). This enables customers not only to quickly generate views of their data but also to create a data presentation layer for analytics.

“Our CHP further demonstrates our commitment to creating innovative solutions for our customers. This allows clients to quickly change or fine-tune reports without the need for costly, time-consuming software development,” said Matt Jennings, CEO and President, Phillips-Medisize. “We are providing the tools needed to extract powerful health and market insights.”

In addition, the CHP can integrate healthcare data from multiple sources thanks to the enterprise master patient index. The data can be made actionable for payers, providers and pharma, allowing patients to be added to specific care pathways. The CHP also allows for data normalization across geographies for global comparison, and data can easily be anonymized or pseudonymized to support clinical or market research.

Clients can be deployed in a secure private cloud. The Phillips-Medisize turnkey offering includes a proven cloud partnership with a credible legacy of health data security. Clients are also able to use many other cloud hosting options or their own data center.

“By offering our platform as a service (PaaS), we're responsible for data security, management and storage. That gives our customers the freedom to focus on what they do best – creating connected health solutions that provide better patient experiences and facilitate improved patient outcomes,” Jennings said.

Phillips-Medisize also helps to lower project costs and accelerate time to market for new connected health solutions. The latest generation CHP comes complete with full regulatory documentation services to support premarket submissions for 501k, combination products and certification mark. In addition, Phillips-Medisize can act as the legal manufacturer for SaMD/MMA, the same service the company provides for the medical devices it manufactures.

Processing. Please wait.
Loading...